Foresee Genomics, a San Francisco, CA-based subsequent technology sequencing (NGS) options firm targeted on the small and medium-sized laboratory market, raised $1.3M in SAFE (Easy Settlement for Future Fairness) Financing.
GoodPaper Ventures supplied the financing.
The corporate intends to make use of the funds to develop operations and its improvement efforts. This marks its ultimate pre-revenue fundraising effort, setting the stage for the graduation of product gross sales in the USA later this 12 months.
Led by CEO Margalit Tocher, and CTO and Founder Dr. Roi Feingersch, Foresee Genomics develops complete options, together with protocols, reagents, and bioinformatics instruments, to make NGS accessible to small and medium-sized laboratories. Its goals to allow these labs to carry out high-accuracy genomic evaluation independently, with out the necessity for expensive infrastructure or excessive minimal portions.
By streamlining the sequencing workflow and optimizing per-sample prices, the corporate helps laboratories present insights that assist personalised affected person care.
Since its founding in 2019, Foresee Genomics has spearheaded three scientific trials and pilot initiatives, two in Israel and one in the USA, and is now getting ready for its business launch.
FinSMEs
29/01/2025
